Fermentalg (FALG) Q2 2024 TU earnings summary

Executive summary

• Achieved record first-half 2024 sales of €6.3 million, up 2.7x year-over-year and surpassing 2022 levels.

• Expanded presence in premium dietary supplements and petfood, with strong North American momentum.

• Strengthened strategic partnership with HuvePharma, including technology transfer and industrial-scale production.

Financial highlights

• First-half 2024 sales reached €6.3 million, compared to €2.3 million in H1 2023 and €5.2 million in H1 2022.

• Annual sales target raised to €12 million for 2024, triple the 2023 figure of €4 million.

Outlook and guidance

• Expects a similarly strong second half of 2024, confirming the new €12 million annual sales target.